Arrhythmias & electrophysiology
Mortality Benefit Among Primary Prevention Implantable Cardioverter-Defibrillator Recipients on Contemporary Heart Failure Treatment
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.757 95% CI 0.678–0.835Authors' conclusion
ICD treatment of patients with a PP indication is associated with improved mortality even in the context of evolving adjunctive HF treatment, consistent with earlier landmark trials.
Study context
- Population
- US patients with a primary prevention ICD indication surviving ≥1 year postindication, EHR data 2012–20202,118 (8.4%) with ICD
- Participants
- 25,296 patients
- Exposure
- ICD vs no ICD
- ICDn = 2,118
- Outcome
- All-cause mortality
Methodological detailspropensity-score matched (4-to-1)
- Propensity-score matched (4-to-1)
Main finding
As reported in the abstract
Hazard ratio
0.757
95% CI 0.678–0.835
P < 0.001
ICDvs No ICD
HR 0.757 (95% CI 0.678–0.835); P < 0.001
Observational data: associations, not effects.
Further findings
ICD benefit, ischemic vs nonischemic heart disease (subgroup)
- No detectable difference in ICD benefit between ischemic and nonischemic heart disease
- P = 0.50
Original publication
Mortality Benefit Among Primary Prevention Implantable Cardioverter-Defibrillator Recipients on Contemporary Heart Failure Treatment. JACC Clin Electrophysiol. Published 20 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →